[Clinical analysis of nimotuzumab plus cisplatin and fluorouracil regimen as induction treatment in resectable head and neck squamous cell carcinoma].

Xiao ying Zhao, Y. Guo, Yong xue Zhu, Y. Wang, Guo pei Zhu, Chao su Hu, Qing hai Ji

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A phase II study was conducted to test the efficacy and toxicity of the combination of cisplatin, 5-Fu and nimotuzumab, as induction treatment of resectable head and neck squamous cell carcinoma (HNSCC). Forty cases of resectable HNSCC were treated with nimotuzumab (400 mg on day 1) combined with PF regimens (cisplatin 75 mg/m2 on days 1 and 5-Fu 750 mg/m2 on days 1-5 q3wks). After 2 cycles, an organ-preservation local therapy (surgery or radiotherapy) was recommended. The primary endpoints of this study were overall response rate, pathologic complete response and safety of the induction treatment. Mean age of 40 patients was 54 years old, of them 9 patients with oropharyngeal cancer (22.5%), 16 hypopharyngeal cancer (40.0%), 10 laryngeal cancer (25.0%), and 5 oral cancer (12.5%). With a 2-cycle induction treatment, 34 (85.0%) patients achieved complete or partial response. Twenty-four patients (60.0%) got downstage, with T downstage in 21 (52.5%) patients and N downstage in 8 (20.0%) patients. Totally 27 patients got surgery after the induction treatment, of them 20 patients (74.1%) preserved organ functions. Four patients' primary tumors (10.0% in all 40 patients and 14.8% in operated 27 patients) showed pathologically complete responses. The toxicity was mild and manageable. The most common grade 3/4 toxicities were neutropenia (5.0%), nausea/vomiting (2.5%), stomatitis (2.5%) and thrombocytopenia (2.5%). One patient got grade 2 renal insufficiency and one patient got grade 1 skin rash. For resectable HNSCC, nimotuzumab plus PF regimen as induction treatment is highly effective for preserving the organ function and the toxicities are well tolerable.

Original languageEnglish (US)
Pages (from-to)536-539
Number of pages4
JournalZhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
Volume47
Issue number7
StatePublished - Jul 2012

Fingerprint

Fluorouracil
Cisplatin
Therapeutics
Carcinoma, squamous cell of head and neck
nimotuzumab
Hypopharyngeal Neoplasms
Oropharyngeal Neoplasms
Organ Preservation
Toxicity Tests
Stomatitis
Laryngeal Neoplasms
Mouth Neoplasms
Exanthema
Neutropenia
Thrombocytopenia
Nausea
Vomiting
Renal Insufficiency
Radiotherapy
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{5913fa9f47da4c55a03d16ebfbcdb015,
title = "[Clinical analysis of nimotuzumab plus cisplatin and fluorouracil regimen as induction treatment in resectable head and neck squamous cell carcinoma].",
abstract = "A phase II study was conducted to test the efficacy and toxicity of the combination of cisplatin, 5-Fu and nimotuzumab, as induction treatment of resectable head and neck squamous cell carcinoma (HNSCC). Forty cases of resectable HNSCC were treated with nimotuzumab (400 mg on day 1) combined with PF regimens (cisplatin 75 mg/m2 on days 1 and 5-Fu 750 mg/m2 on days 1-5 q3wks). After 2 cycles, an organ-preservation local therapy (surgery or radiotherapy) was recommended. The primary endpoints of this study were overall response rate, pathologic complete response and safety of the induction treatment. Mean age of 40 patients was 54 years old, of them 9 patients with oropharyngeal cancer (22.5{\%}), 16 hypopharyngeal cancer (40.0{\%}), 10 laryngeal cancer (25.0{\%}), and 5 oral cancer (12.5{\%}). With a 2-cycle induction treatment, 34 (85.0{\%}) patients achieved complete or partial response. Twenty-four patients (60.0{\%}) got downstage, with T downstage in 21 (52.5{\%}) patients and N downstage in 8 (20.0{\%}) patients. Totally 27 patients got surgery after the induction treatment, of them 20 patients (74.1{\%}) preserved organ functions. Four patients' primary tumors (10.0{\%} in all 40 patients and 14.8{\%} in operated 27 patients) showed pathologically complete responses. The toxicity was mild and manageable. The most common grade 3/4 toxicities were neutropenia (5.0{\%}), nausea/vomiting (2.5{\%}), stomatitis (2.5{\%}) and thrombocytopenia (2.5{\%}). One patient got grade 2 renal insufficiency and one patient got grade 1 skin rash. For resectable HNSCC, nimotuzumab plus PF regimen as induction treatment is highly effective for preserving the organ function and the toxicities are well tolerable.",
author = "Zhao, {Xiao ying} and Y. Guo and Zhu, {Yong xue} and Y. Wang and Zhu, {Guo pei} and Hu, {Chao su} and Ji, {Qing hai}",
year = "2012",
month = "7",
language = "English (US)",
volume = "47",
pages = "536--539",
journal = "Zhonghua er bi yan hou ke za zhi",
issn = "1673-0860",
publisher = "Zhonghua Yixuehui Zazhishe",
number = "7",

}

TY - JOUR

T1 - [Clinical analysis of nimotuzumab plus cisplatin and fluorouracil regimen as induction treatment in resectable head and neck squamous cell carcinoma].

AU - Zhao, Xiao ying

AU - Guo, Y.

AU - Zhu, Yong xue

AU - Wang, Y.

AU - Zhu, Guo pei

AU - Hu, Chao su

AU - Ji, Qing hai

PY - 2012/7

Y1 - 2012/7

N2 - A phase II study was conducted to test the efficacy and toxicity of the combination of cisplatin, 5-Fu and nimotuzumab, as induction treatment of resectable head and neck squamous cell carcinoma (HNSCC). Forty cases of resectable HNSCC were treated with nimotuzumab (400 mg on day 1) combined with PF regimens (cisplatin 75 mg/m2 on days 1 and 5-Fu 750 mg/m2 on days 1-5 q3wks). After 2 cycles, an organ-preservation local therapy (surgery or radiotherapy) was recommended. The primary endpoints of this study were overall response rate, pathologic complete response and safety of the induction treatment. Mean age of 40 patients was 54 years old, of them 9 patients with oropharyngeal cancer (22.5%), 16 hypopharyngeal cancer (40.0%), 10 laryngeal cancer (25.0%), and 5 oral cancer (12.5%). With a 2-cycle induction treatment, 34 (85.0%) patients achieved complete or partial response. Twenty-four patients (60.0%) got downstage, with T downstage in 21 (52.5%) patients and N downstage in 8 (20.0%) patients. Totally 27 patients got surgery after the induction treatment, of them 20 patients (74.1%) preserved organ functions. Four patients' primary tumors (10.0% in all 40 patients and 14.8% in operated 27 patients) showed pathologically complete responses. The toxicity was mild and manageable. The most common grade 3/4 toxicities were neutropenia (5.0%), nausea/vomiting (2.5%), stomatitis (2.5%) and thrombocytopenia (2.5%). One patient got grade 2 renal insufficiency and one patient got grade 1 skin rash. For resectable HNSCC, nimotuzumab plus PF regimen as induction treatment is highly effective for preserving the organ function and the toxicities are well tolerable.

AB - A phase II study was conducted to test the efficacy and toxicity of the combination of cisplatin, 5-Fu and nimotuzumab, as induction treatment of resectable head and neck squamous cell carcinoma (HNSCC). Forty cases of resectable HNSCC were treated with nimotuzumab (400 mg on day 1) combined with PF regimens (cisplatin 75 mg/m2 on days 1 and 5-Fu 750 mg/m2 on days 1-5 q3wks). After 2 cycles, an organ-preservation local therapy (surgery or radiotherapy) was recommended. The primary endpoints of this study were overall response rate, pathologic complete response and safety of the induction treatment. Mean age of 40 patients was 54 years old, of them 9 patients with oropharyngeal cancer (22.5%), 16 hypopharyngeal cancer (40.0%), 10 laryngeal cancer (25.0%), and 5 oral cancer (12.5%). With a 2-cycle induction treatment, 34 (85.0%) patients achieved complete or partial response. Twenty-four patients (60.0%) got downstage, with T downstage in 21 (52.5%) patients and N downstage in 8 (20.0%) patients. Totally 27 patients got surgery after the induction treatment, of them 20 patients (74.1%) preserved organ functions. Four patients' primary tumors (10.0% in all 40 patients and 14.8% in operated 27 patients) showed pathologically complete responses. The toxicity was mild and manageable. The most common grade 3/4 toxicities were neutropenia (5.0%), nausea/vomiting (2.5%), stomatitis (2.5%) and thrombocytopenia (2.5%). One patient got grade 2 renal insufficiency and one patient got grade 1 skin rash. For resectable HNSCC, nimotuzumab plus PF regimen as induction treatment is highly effective for preserving the organ function and the toxicities are well tolerable.

UR - http://www.scopus.com/inward/record.url?scp=84874912720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874912720&partnerID=8YFLogxK

M3 - Article

C2 - 22932235

AN - SCOPUS:84874912720

VL - 47

SP - 536

EP - 539

JO - Zhonghua er bi yan hou ke za zhi

JF - Zhonghua er bi yan hou ke za zhi

SN - 1673-0860

IS - 7

ER -